Company / Cash & Equivalents
MEDICINOVA INC Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$30.8M
FY2025
5-year range
$18.5M / $71.4M
FY2021-FY2025
Trend
-23.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $4M in FY2013 to $71M in FY2021.
Based on SEC 10-K filings.
$31M in FY2025 with a 3-year CAGR of +18.5%.
Declined from $51M to $31M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +18.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +18.5%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 23.7% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.8M | -23.7% |
| FY2024 | $40.4M | -20.9% |
| FY2023 | $51.0M | +175.6% |
| FY2022 | $18.5M | -74.1% |
| FY2021 | $71.4M | +512.1% |
| FY2014 | $11.7M | +191.0% |
| FY2013 | $4.0M | -73.4% |
| FY2012 | $15.1M | +0.0% |
| FY2011 | $15.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026